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Abstract 918 
 919 
Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best 920 
approach to integrated care pathways (ICPs) using mobile technology in AR and asthma 921 
multimorbidity. The proposed next phase of ARIA is Change Management (CM) with the aim of 922 
providing an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity 923 
across the life cycle whatever their gender or socio-economic status in order to reduce health and 924 
social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and 925 
implement the impact of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A 926 
second change management strategy is proposed by ARIA Phase 4 to increase self-medication and 927 
shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the 928 
development and validation of IT evidence-based tools (MASK: Mobile Airways Sentinel Network) 929 
that can inform patient decisions on the basis of a self-care plan proposed by the health care 930 
professional.     931 
 Article type: Rostrum 932 
Key words: Change management, rhinitis, asthma, ARIA,  933 
Word count: 3852 934 
1 Table 935 
4 Figures 936 
Abstract word count: 165 937 
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Abbreviations 940 
AHA: Active and Healthy Ageing  941 
AIRWAYS ICPs: Integrated care pathways for airway diseases 942 
AIT: Allergen immunotherapy 943 
AR: Allergic rhinitis 944 
ARIA: Allergic Rhinitis and its Impact on Asthma 945 
BAMSE: Barn Allergi Milj. Stockholm Epidemiologi Projektet    946 
CDSS: Clinical decision support system 947 
CM: Change management 948 
CM2: Second phase of change management 949 
DG CONNECT: Directorate General for Communications Networks, Content & Technology 950 
DG Santé: Directorate General for Health and Food Safety 951 
DG: Directorate General 952 
EAACI: European Academy of Allergy and Clinical Immunology 953 
EFA: European Federation of Allergy and Airways Diseases Patients’ Associations  954 
EGEA: Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy 955 
EIP on AHA:  European Innovation Partnership on Active and Healthy Ageing  956 
EIP: European Innovation Partnership 957 
ELF: European Lung Foundation 958 
EQ-5D: Euroquol 959 
ERS: European Respiratory Society 960 
EUFOREA: European Forum for Research and Education in Allergy 961 
GARD: WHO Global Alliance against Chronic Respiratory Diseases 962 
HCP: Health care professional 963 
ICP: Integrated care pathway 964 
ICT: Information and communication technology 965 
IT:  Information technology 966 
JA-CHRODIS: Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle 967 
MACVIA-LR: contre les MAladies Chroniques pour un VIeillissement Actif (Fighting chronic diseases for AHA) 968 
MASK: Mobile Airways Sentinel network 969 
MAS: German Multicenter Allergy Study 970 
MeDALL: Mechanisms of the Development of Allergy 971 
mHealth: mobile health 972 
OTC: Over the counter 973 
POLLAR: Impact of air POLLution on Asthma and Rhinitis 974 
QOL: Quality of life 975 
SCUAD: Severe chronic upper airway disease 976 
SDM: Shared decision making 977 
TRL: Technology Readiness level 978 
VAS: Visual analogue scale 979 
WHO: World Health Organization 980 
WPAI-AS: Work Productivity and Activity questionnaire 981 
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Introduction 982 
Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best 983 
approach 1,5 to integrated care pathways (ICPs) using mobile technology in AR and asthma 984 
multimorbidity 6. The term co-morbidity is commonly used for allergic diseases, but multimorbidity 985 
might be more appropriate. Comorbidity is the presence of one or more additional diseases co-986 
occurring with a primary disease or the effect of such additional disorders or diseases. Multimorbidity 987 
is a term which means co-occurring diseases in the same patient 7, 8. 988 
ARIA provides an evidence-based approach for managing the patient’s needs but real-life data have 989 
shown that few patients use guidelines and that they often self-medicate (Menditto, in preparation). 990 
Moreover, patients largely use OTC medications dispensed in pharmacies 9,11. Self-care and shared 991 
decision making (SDM) centered around the patient should be used more frequently. 992 
Change is inevitable in health care. ARIA has followed a change management (CM) strategy in the 993 
past, but a new revised plan should be considered in order to fill the gaps of knowledge translation into 994 
practice and to increase the benefits of self-care in care pathways (ICPs) using the currently-available 995 
ICT tools 12. These changes should prepare and support individuals, teams and organizations in 996 
making organizational change centered around the patient for more efficient care. 997 
1- Background 998 
1-1- The four ARIA phases 999 
 ARIA was initiated during a World Health Organization (WHO) workshop in 1999 2 and has evolved 1000 
in four phases: 1001 
Phase 1:  Development of an evidence-based document to provide a guide for the diagnosis and 1002 
management of AR and asthma multimorbidity 1, 2. In 2008, ARIA was updated using the same 1003 
recommendation system 1, 13. ARIA has been disseminated and is implemented in over 70 countries 1004 
around the world 14. 1005 
Phase 2: In its 2010 Revision, ARIA was the first chronic respiratory disease guideline to adopt the 1006 
GRADE (Grading of Recommendation, Assessment, Development and Evaluation) approach, an 1007 
advanced evidence evaluation and recommendation methodology for guidelines 3,5. When guidelines 1008 
are made using the same methodology, the recommendations are similar 5, 15. 1009 
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Phase 3: ARIA focused on the implementation of emerging technologies for individualized and 1010 
predictive medicine to develop ICPs for the management of AR and asthma by a multi-disciplinary 1011 
group centered around the patients 16,19,20,23 (MASK: Mobile Airways Sentinel Network). 1012 
The proposed ARIA phase 4 is CM to provide an active and healthy life to rhinitis and asthma 1013 
sufferers across the life cycle whatever their gender or socio-economic status with the aim to reduce 1014 
health and social inequities globally. 1015 
1-2- Shared decision making and patient empowerment  1016 
In SDM, both the patient and the physician contribute to the medical decision-making process, placing 1017 
the patient at the centre of the decision-making paradigm 24. Physicians explain treatments and 1018 
alternatives to patients who then choose the treatment option that best aligns with their beliefs, 1019 
lifestyles and goals along with the benefits and risks 25. In contrast to SDM, the traditional medical 1020 
care system places physicians in a position of authority, with patients playing a passive role in care. 1021 
Patients want greater involvement in SDM 26. An innovation of SDM in ARIA is the use of IT 1022 
evidence-based tools that can inform patient decisions on the basis of a guided self-management plan 1023 
proposed by their health care professionals 27. In asthma, the effectiveness of four SDM studies shows 1024 
improvement of control and some other parameters but more studies are needed to confirm the data 28.  1025 
1-3- Change management 1026 
Change is inevitable in health care. However, many change projects fail due to varied belief and 1027 
cultural circumstances, poor planning, unmotivated staff, deficient communication, or excessively 1028 
frequent changes 29.  1029 
CM aims to prepare and support individuals, teams and organizations in making organizational 1030 
change. It proposes methods redirecting or redefining resources, business processes, budget allocation 1031 
and/or modes of operation. When properly applied, CM significantly changes healthcare and its 1032 
organization. However, health systems differ largely between countries or even regions and a 1033 
combination of CM with ICPs may be more relevant allowing each organization to use the CM 1034 
principles according to their needs and regulations. CM deals with different disciplines from 1035 
healthcare, behavioral and social sciences to IT and business solutions. 1036 
Although theories may seem abstract and impractical for healthcare practice, they can help in planning 1037 
solutions to common healthcare problems 29. The Lewin’s 3-Step model is widely used 30,31: 1038 
unfreezing, moving, and refreezing 31. Lippitt 32 and  Kotter 12 have added intermediate steps (Table 1) 1039 
29
.  1040 
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Several models of organizational and personal change have been reviewed for respiratory diseases 33. 1041 
Kotter’s theory has been applied to different fields of medicine 34,36 and pharmacies 37. 1042 
2- ARIA Phases 1 and 2 followed the Kotter’s 8-step change model 1043 
2-1- Goals 1044 
Guidelines such as GINA (Global INitiative for Asthma) 38,39, GOLD (Global initiative for Lung 1045 
Diseases) 40,41, EPOS 42 and ARIA 2, 3, 13 developed a CM strategy that was very effective and produced 1046 
many updates and revisions while having a positive impact on clinical care and influencing research 1047 
priorities. 1048 
Most guidelines are condition specific but ARIA was unique as it included for the first time the 1049 
multimorbid component of the airway diseases. Although it followed the patient’s perspectives, 1050 
epidemiologic evidence 43 and some supporting mechanistic studies 44, this concept was not accepted 1051 
by the leadership of GINA who considered neither the asthma-rhinitis multimorbidity concept nor the 1052 
benefit for the patients.   1053 
2-2- The 8-step model 1054 
2-2-1- Establish a sense of urgency 1055 
The sense of urgency should identify and highlight the potential threats and the repercussions that 1056 
might arise in the future by examining the opportunities which can be tapped through effective 1057 
interventions. In AR and asthma, in the 1990s, the sense of urgency was to provide guidelines that 1058 
could reduce both the burden of the diseases and the deaths (in asthma). Although there were papers 1059 
indicating the links between the upper and lower airways 45, 46, the impact of rhinitis on asthma was not 1060 
fully recognized and ARIA was initiated to better reconize the inter-relationships between the two 1061 
diseases and to propose multimorbid guidelines.   1062 
2-2-2- Create a guiding coalition 1063 
The ARIA working group was initiated during a WHO meeting (December 1999) and evolved as a 1064 
powerful group with 400 members in 70 countries 14. Members have been working together for years 1065 
and include all stakeholders needed for CM 1,6. The patients’ organization EFA (European Federation 1066 
of Allergy and Airways Diseases Patients’ Associations) has always been an active member of ARIA.   1067 
2-2-3- Develop a vision and strategy 1068 
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The ARIA vision has always been to provide a guide for the diagnosis and management of AR and 1069 
asthma multimorbidity, including developing countries,1, 2 using the best available evidence 3,5.  ARIA 1070 
has established two major targets: the recognition and implementation of the asthma-rhinitis 1071 
multimorbidity as well as a new classification (intermittent-persistent and mild-moderate severe AR) 1072 
to meet patients’ expectations. Moreover, ARIA priorities have always included primary care 1073 
physicians, pharmacists and patients’ organizations.  1074 
2-2-4- Communicate the change vision 1075 
One of the ARIA strengths has been to communicate its vision effectively worldwide. Over 1,000 1076 
papers have been posted on Pubmed from over 50 countries using the ARIA recommendations 14. The 1077 
number of training sessions in over 70 countries cannot be counted. ARIA has been endorsed by many 1078 
governments and international organizations: ARIA recommendations have been used for the labeling 1079 
of allergen immunotherapy by the European Medicine Agency. 1080 
2-2-5- Empower others to act on the vision 1081 
Organizational processes and structures are in place and are aligned with the overall organizational 1082 
vision. However, a continuous check is needed for barriers and for people who are resisting change. 1083 
We have implemented proactive actions to remove the obstacles involved in the process of change.  1084 
ARIA has been recognized as the major rhinitis and asthma multimorbidity guideline for years in most 1085 
countries except for the US and Japan. However, the recent US guidelines are using the evidence-1086 
based approach of ARIA (GRADE: Grading of Recommendations, Assessment, Development and 1087 
Evaluation), and the recommendations are similar 15, 47, 48 to those of ARIA 5. The recent Japanese 1088 
guidelines for AR are also making bridges with ARIA 49.   1089 
2-2-6- Generate short-term wins 1090 
As proposed by Kotter 12, creating short-term wins early in the change process, instead of having one 1091 
long-term goal, can give a feeling of victory in the early stages of change, which will reinforce support 1092 
to the strategy.  1093 
The concept of asthma and rhinitis multimorbidity is now globally accepted in developed and 1094 
developing countries 50. It is now recognized that multimorbidity is independent of IgE-mediated 1095 
allergy 8, 51 and new phenotypes of severe airway disease have been identified. The implementation of 1096 
the multimorbid concept in clinical practice has a direct benefit for the patient whose nasal symptoms 1097 
are often more bothersome than asthma. 1098 
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2-2-7- Consolidate gains and produce more change 1099 
The goals of step 7 12 are to achieve continuous improvement by analysing the success stories 1100 
individually and improving from those individual experiences. These goals are exactly those that have 1101 
been followed by ARIA for the past 18 years. 1102 
2-2-8- Anchor new approaches in the culture and institutionalize the changes 1103 
The goals of step 8 12 are met by the ARIA strategy: 1104 
1. Discuss widely the successful stories related to change initiatives. 1105 
2. Ensure that the change becomes an integral part of the practice and is highly visible. 1106 
3. Ensure that the support of the existing as well as the new leaders continues to extend towards the 1107 
change. 1108 
2-3- Results, drawbacks and solutions 1109 
ARIA has fully achieved its goals following the 8-step Kotter’s model of (Figure 1). The outcome 1110 
assessment can be measured (i) by the numbers of citations of ARIA. ARIA 2001 has been cited 1750 1111 
times, ARIA 2008 over 2300 times (only paper in asthma cited >200 times a year) and ARIA 2010 1112 
710 times. This initiative is far better cited than GINA. (ii) By the countries that have endorsed ARIA 1113 
in their national allergy program: Finland, Malaysia, Philippines, Portugal, Singapore. (iii) By the 1114 
approval of treatments by agencies: The European Medicines Agency used the ARIA classification in 1115 
the approval of Acarizax® (mite sublingual immunotherapy). 1116 
Some drawbacks have been pointed out in Kotter’s change model 12. In particular, the model is 1117 
essentially top-down and may discourage any scope for participation or co-creation. In ARIA, we 1118 
considered that the first CM model was a great success but that it’s life cycle had come to an end. It 1119 
was then decided within the coalition to propose a new CM model based on patients’ needs and 1120 
emerging technologies (CM2 model).  1121 
Since the Kotter model cannot be redesigned, we proposed a new maturity CM model based on the 1122 
same Kotter’s 8-step change model 12. We used ARIA Phase 3 (care pathways for rhinitis and asthma 1123 
multimorbidity using mobile technology) 6 to better plan the second CM model (CM2 model) and 1124 
make new assumptions with a patient’s centered approach. 1125 
3-  The Allergy Diary strengthens change management 1126 
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 3-1- MASK 1127 
In 2012, the European Commission launched the European Innovation Partnership on Active and 1128 
Healthy Ageing (DG Santé and DG CONNECT) (52). The B3 Action Plan, devoted to innovative 1129 
integrated care models for chronic diseases, selected integrated care pathways for airway diseases 1130 
(AIRWAYS ICPs) 53, 54 with a life cycle approach 55 as the model of chronic diseases. An AIRWAYS 1131 
ICPs Action Plan  was devised 53, implemented 54 and scaled up 56, 57. AIRWAYS ICPs is a GARD 1132 
(WHO Global Alliance for Chronic Respiratory Diseases) 58 research demonstration project (Figure 1133 
2). 1134 
MASK, the ARIA Phase 3, is an AIRWAYS ICPs tool 6, 59. It represents a Good Practice focusing on 1135 
the implementation of multi-sectoral care pathways using emerging technologies with real life data in 1136 
rhinitis and asthma multi-morbidity. MASK follows the JA-CHRODIS (Joint Action on Chronic 1137 
Diseases and Promoting Healthy Ageing across the Life Cycle, 2nd EU Health Programme 2008-2013 1138 
60) recommendations for good practices 18.   1139 
MASK was initiated to reduce the global burden of rhinitis and asthma, by giving the patient a simple 1140 
tool to better prevent and manage respiratory allergic diseases. More specifically, MASK should help 1141 
to (i) understand the disease mechanisms and the effects of air pollution in allergic diseases (ii) better 1142 
appraise the burden incurred by medical needs but also indirect costs, (iii) propose novel 1143 
multidisciplinary care pathways integrating pollution and patients’ literacy, (iv) improve work 1144 
productivity, (v) propose the basis for a sentinel network at the EU level for pollution and allergy and 1145 
(vi) assess the societal implications of the project to reduce health and social inequalities globally. 1146 
 3-2- The Allergy Diary    1147 
 The mobile technology of MASK is the Allergy Diary, an App (Android and iOS) freely available for 1148 
AR and asthma sufferers in 23 countries (16 EU countries, Argentina, Australia, Brazil, Canada, 1149 
Mexico, Switzerland and Turkey) and 16 languages (translated and back-translated, culturally adapted 1150 
and legally compliant) 6 (Figure 3). Anonymized users fill in a simple questionnaire on asthma and 1151 
rhinitis upon registration and daily assess the impact of the disease using a visual analogue scale 1152 
(VAS) 61 for global allergy symptoms, rhinitis, conjunctivitis, asthma and work. Moreover, a 1153 
questionnaire is applied every week to assess disease impact on patients’ QOL (EQ-5D) 21.  1154 
Data of pilot studies in up to 17,000 users and over 95,000 days are available. The Allergy Diary has 1155 
been validated 19 and has shown that (i) totally anonymized geolocation can be used in 23 countries (in 1156 
preparation), (ii) data can be analyzed in 23 countries and 17 languages, (iii) sleep, work productivity 1157 
and daily activities are impaired in AR 16, 17, (iv) daily work productivity is associated with AR 1158 
severity 16, (v) the everyday use of medications can be monitored proposing a novel assessment of 1159 
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treatment patterns 20, (vi) novel patterns of multimorbidity have been identified 22 and confirmed in 1160 
epidemiological studies 8, 62 and (vii) over 70% of AR patients self-medicate and are non-adherent to 1161 
medications (Menditto, in preparation).   1162 
The Allergy Diary (TRL 9, Technology Readiness level 9) represents a validated mHealth tool for the 1163 
management of AR. Asthma has also been monitored but data have not yet been analyzed. Economic 1164 
impact can be monitored using work productivity. The results of the Allergy Diary have made 1165 
innovative approaches of AR possible and are directly strengthening CM strategies in ARIA.  1166 
 3-3- Transfer of Innovation of MASK 1167 
A Transfer of Innovation (Twinning) project has been funded by the European Innovation Partnership 1168 
on Active and Healthy Ageing (EIP on AHA) using MASK in 25 Reference Sites or regions across 1169 
Europe, Argentina, Australia, Brazil, Columbia and Mexico 63. The number of countries is increasing 1170 
and MASK should be rapidly operative in the US, China, India (in English only) and Japan. This will 1171 
improve the understanding, assessment of burden, diagnosis and management of rhinitis in old age by 1172 
comparison with an adult population. The Twinning has been tested in Germany (Region Kohln-1173 
Bonn) in a pilot study that has now been extended to the other German cities and countries of the 1174 
Twinning project. 1175 
 3-4- Clinical decision support system 1176 
Clinical decision support systems (CDSS) are software algorithms that advise health care providers on 1177 
the diagnosis and management of patients based on the interaction of patient data and medical 1178 
information. They should be based on the best evidence to aid patients and health care professionals to 1179 
jointly determine treatment (SDM). In allergic rhinitis, the MASK CDSS is incorporated into a tablet 1180 
interoperable with the Allergy Diary 64 for health care professionals (ARIA Allergy Diary Companion) 1181 
6, 59
. This is based on an algorithm to aid clinicians to select pharmacotherapy for AR patients and to 1182 
stratify their disease severity 65. This approach will be adapted for the patient’s guided self-care in a 1183 
context of SDM.  1184 
3-5- POLLAR 1185 
Interactions between air pollution, sleep and allergic diseases are clear but insufficiently understood. 1186 
POLLAR (Impact of Air POLLution in Asthma and Rhinitis) is a new Horizon 2020 project of the 1187 
EIT Health (European Institute of Innovation and Technology for Health) that will embed 1188 
environmental data into the Allergy Diary. POLLAR aims at combining emerging technologies 1189 
(including the Allergy Diary, Technology Readiness level TRL9 meaning that the system is proven in 1190 
operational environment) with machine learning to (i) understand the effects of air pollution in AR and 1191 
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its impact on sleep, work and asthma, (ii) assess societal consequences, shared with citizens, and 1192 
professionals (iii) propose preventive strategies including a sentinel network and (iv) develop 1193 
participative policies. 1194 
4- ARIA Phases 3 and 4 deploy a novel Kotter’s 8-step change model 1195 
4-1- Goals 1196 
Although the first CM model developed by the ARIA Initiative was a great success, there are still 1197 
unmet needs in the treatment of asthma and rhinitis multimorbidity.  In ARIA Phase 4, we encourage 1198 
the participation of all the stakeholders.  1199 
4-2- The 8-step model 1200 
4-2-1- Establish a sense of urgency 1201 
ICPs will include multi-disciplinary structured care plans detailing the key steps of patient care 1202 
including self-care as proposed by AIRWAYS ICPs 53 (Integrated care pathways for airway diseases). 1203 
GRADE-based guidelines for physicians are available for AR and their recommendations are similar 3, 1204 
5, 15
. However, they are based on the assumption that patients regularly use their treatment and are not 1205 
tested with real-life data. Unfortunately, adherence to treatment is very low and real-life studies do not 1206 
necessarily accord with all recommendations 20. New-generation guidelines embedding real life data 1207 
are being developed. 1208 
4-2-2- Create a guiding coalition 1209 
The ARIA working group initiated in 1999 includes over 500 members in 70 countries 14. A successful 1210 
coalition working on CM2 has been identified within the group. 1211 
The AIRWAYS ICPs coalition was established in 2014 and is part of the European Innovation 1212 
Partnership on Active and Healthy Ageing (DG Santé and DG CNECT) 53. Moreover, many national 1213 
and European scientific societies (European Academy of Allergy and Clinical Immunology (EAACI), 1214 
European Respiratory Society (ERS) and International Primary Care Respiratory Group (IPCRG)), 1215 
and other patients’ organization (European Lung Foundation (ELF), Asthma UK) have joined the 1216 
coalition. It is a WHO GARD (WHO Global Alliance against Chronic Respiratory Diseases) 1217 
demonstration project. Finally, the transfer of innovation of ARIA has been carried out to the 1218 
Reference Sites of the European Innovation Partnership on Active and Healthy Ageing 63. 1219 
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This CM2 guiding coalition is already in place in EUFOREA (European Forum for Research and 1220 
Education in Allergy and Airways Diseases, http://www.euforea.eu) 66. 1221 
4-2-3- Develop a vision and strategy 1222 
The vision of ARIA phase 4 is to provide CM2 for AR and asthma multimorbidity in order to develop 1223 
SDM with the ultimate goal of improving AR and asthma control while maintaining quality-of-life 1224 
and reducing costs, using mobile technology and real-time data management to inform decisions.  1225 
The strategy for realizing the changes is based on the patient-centered implementation of ICPs 53 using 1226 
IT solutions such as the Allergy Diary 6. 1227 
4-2-4- Communicate the change vision 1228 
The updated vision (CM2) will use the experience of the first CM strategy. It has already been 1229 
discussed among the ARIA CM coalition members and the present paper is the first to be published. 1230 
However, it takes time to address the concerns of all stakeholders, and papers published recently on 1231 
the Allergy Diary may help to convince many. ARIA is involving a maximum number of people to 1232 
deploy the CM vision. 1233 
The integration of new paths of understanding health and change is a requirement for the strategy. The 1234 
CM2-model clearly expands and strengthens the potential for actual change to occur and take hold in 1235 
all kinds of organizations and institutions. Supplementary to the ambition of change in existing 1236 
practices and institutions, it is also important to consider the integration of other modes of 1237 
communication and dissemination on the basis of healthy behaviour.  A central example is the general 1238 
need to raise the level of health literacy in society. The general public should clearly not be perceived 1239 
simply as “patients waiting for something to happen”. They should have the ability to navigate and 1240 
understand health messages, an essential tool for self-managing wellbeing, even before any actual 1241 
condition or major challenge actually occurs. But to do so, one must consider how to improve this 1242 
health literacy by integrating it much better into the educational system and cultural settings to which 1243 
it applies. This is a very long-term investment in self-care and prevention. A later target audience with 1244 
a higher level of health literacy will naturally also ensure an easier adoption of subsequent health 1245 
messages, possibly using ICT 67. The basis for understanding is simply enhanced compared to the 1246 
previous scenario. In a similar line of thinking, one could also consider a wider community-oriented 1247 
approach to dissemination. This could also cover social media and self-help groups, as some of the 1248 
later patients would benefit not only from both personal previous experience and knowledge about 1249 
these ailments, but also from a supportive environment, that would be better able to support and help 1250 
these citizens/friends/family members – regardless of age – in their attempt to adapt to new modes of 1251 
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behavior. This is a wider application of the CM2-model and should also be considered in our work to 1252 
help patients and citizens. 1253 
4-2-5- Empower others to act on the vision 1254 
Organizational processes and structures are in place and are aligned with the overall organizational 1255 
vision. However, we need to continuously check for barriers and for those who are resistant to change 1256 
and focus on the education of both physicians and patients on how to achieve the best outcomes of 1257 
treatment. We are acting proactively to remove the obstacles involved in the process of change.  1258 
    4-2-6- Generate short-term wins 1259 
We propose to create new short-term (e.g. 12 months) and medium-term (e.g. 24 months) targets. In 1260 
2018, a high-level meeting organized by POLLAR will approach the improvement in care pathway 1261 
design to enhance patient participation, health literacy and self-care through technology-assisted 1262 
‘patient activation’. In this meeting, rhinitis and asthma multimorbidity will be used as a model of 1263 
non-communicable disease (Figure 4). Three major aspects of ICPs will be considered: self-care, 1264 
pharmacy care and next-generation guidelines in which the recommendations of the GRADE-1265 
guidelines on AR 5, 15 will be tested in real life using MASK. 1266 
4-2-7- Consolidate gains and produce more change 1267 
Most of the goals of Kotter’s change model step-7 12 have been met by the ARIA CM and will be 1268 
further developed in CM2. 1269 
 1270 
Conclusions 1271 
For the past 18 years, ARIA has had the major goal of providing a guide for the diagnosis and 1272 
management of AR and asthma multimorbidity applicable to developing countries 1, 2 using the best 1273 
evidence 3-5. ARIA Phases 1 and 2 were developed in accordance to Kotter’s 8 step change model and 1274 
can be used as a model of CM in chronic diseases. However, there are still unmet needs for the 1275 
management of rhinitis and asthma in real life. 1276 
A second CM model has been proposed by ARIA Phases 3 and 4. It was initiated by the development 1277 
in 23 countries of an App that showed partly unexpected results. Patients with AR (and possibly with 1278 
asthma) do not follow physicians’ advice: they self-medicate. There is an urgent need to harness this 1279 
information and to update our concept of treatment as well as treatment adherence using mobile 1280 
technology and care pathways. This is the goal of ARIA Phase 4 and the second wave of CM. 1281 
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Table 1: Examples of planned change management models. Adapted from (31) 1467 
 1468 
Lewin (68) Kotter (12) Lippitt (32) 
Unfreezing 
Step 1: Establish a sense of urgency 
Step 2: Create a guiding coalition 
Step 3: Develop a vision and strategy 
Phase 1: Diagnose the problem 
Phase 2: Assess motivation and capacity for change 
Phase 3: Assess change agent’s motivation and 
resources 
Moving 
Step 4: Communicate the change vision 
Step 5: Empower others to act on the vision 
Step 6: Generate short-term wins 
Step 7: Consolidate gains and produce more 
change 
 
Phase 4: Select a progressive change objective 
Phase 5: Choose appropriate role of the change agent 
Refreezing 
Step 8: Anchor new approaches in the culture  
and institutionalize the changes 
Phase 6: Terminate the helping relationship 
 1469 
 1470 
 1471 
 1472 
  1473 
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Figure 1: Change management strategy of ARIA Phases 1 and 2     1474 
ARIA: Allergic Rhinitis and its Impact on Asthma, BAMSE: Barn Allergi Milj. Stockholm Epidemiologi Projektet , EGEA: 1475 
Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy, GRADE, 1476 
MAS: German Multicenter Allergy Study, MASK: Mobile Airways Sentinel network, MeDALL: Mechanisms of the 1477 
Development of Allergy, SDM: Share decision making, T2: Type 2 immunity 1478 
Figure 2: Links between ARIA and MASK for change management 1479 
AIRWAYS-ICPs: Integrated Care Pathways for airway diseases (European Innovation Partnership on Active and 1480 
Healthy Ageing), WHO CC: World Health Organisation Collaborating Center, DigitalHealthEurope: Digital 1481 
Transformation of Health in Europe (H2020), Euriphi: Better Health and care, economic growth and sustainable 1482 
health systems (H2020), GA2LEN: Global Allergy and Asthma European network (FP6), GARD: Global Alliance against 1483 
Chronic Respiratory Diseases, Good Practice of DG Santé: Good Practice on digitally-enabled, integrated, person-1484 
centred care of the Directorate-General for Health and Food Safety (European Commission), ICP: Integrated care 1485 
pathway, MACVIA-LR: Contre les Maladies Chroniques pour un Vieillisement Actif (European Innovation Partnership 1486 
on Active and Healthy Ageing), MeDALL: Mechanisms of the Development of ALLergy (FP7), POLLAR: Impact of air 1487 
POLLution in Asthma and Rhinitis (EIT Health), SPAL: EU Development and Structural Funds, Sunfrail, Twinning: 1488 
Vigour: (Evidence-Based Guidance to Scale-up Integrated Care in Europe, 3rd Health Programme).  1489 
 1490 
Figure 3: The Allergy Diary 1491 
 1492 
GPDR: General Data Protection Regulation (https://www.eugdpr.org) 1493 
 1494 
 1495 
Figure 4: Change management based on next-generation ICPs   1496 
  1497 
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